Between 1990 and 1997, 55 patients with high risk multiple myeloma underwent high-dose therapy with peripheral blood stem cell transplantation. Intensification consisted of high-dose L-PAM in 54 patients, and 15 patients underwent a second high-dose treatment. Thirty patients received total body irradiation. Twenty patients were more than 60 years old. Thirty-five patients were intensified during first response. The overall response rate was 78%. There were four toxic deaths. The median overall survivals after intensification and after first treatment of myeloma were greater than 48 months and 71 months, respectively. Conversely freedom from progression after intensification was short, with a median of 22 months. Freedom from progression was significantly shorter in patients older than 60 (12 months), and in patients who had received more than 75 mg/m 2 of L-PAM before intensification (16 months). Although intensification is feasible in elderly patients the benefit appears to be reduced in this subgroup of patients. Prior therapy with high cumulative doses of L-PAM should be avoided in patients who will receive high-dose L-PAM for therapeutic intensification. Keywords: myeloma; elderly; L-PAM; PBSC The alkylating agents L-PAM and cyclophosphamide were the first agents to significantly increase the median survival in patients with high risk myeloma, from 7 to 30 months after diagnosis. The administration of high-dose L-PAM, alone or with growth factors and/or stem cell support has yielded encouraging results in a number of non-randomized series, with higher response rates, including a large fraction of complete or very good partial responses. at 5 years vs 12%) than the use of standard-dose chemotherapy.
The alkylating agents L-PAM and cyclophosphamide were the first agents to significantly increase the median survival in patients with high risk myeloma, from 7 to 30 months after diagnosis. The administration of high-dose L-PAM, alone or with growth factors and/or stem cell support has yielded encouraging results in a number of non-randomized series, with higher response rates, including a large fraction of complete or very good partial responses. [1] [2] [3] [4] In a randomized study, Attal et al 5 have shown that high-dose L-PAM 140 mg/m 2 , TBI (8 Gy) and bone marrow grafting after induction chemotherapy by VBAP/VMCP chemotherapy allowed significantly longer overall survival (52% Correspondence: C Dumontet, Service d'Hématologie, Centre Hospitalier Lyon Sud, Chemin du Grand Revoyet, 69495, Pierre Bénite, Cedex, France Received 15 September 1997; accepted 9 January 1998 at 5 years vs 12%) than the use of standard-dose chemotherapy.
A major concern with the use of bone marrow grafts is the potential role played by contaminating myeloma cells in relapse. Various authors have advocated the use of peripheral blood stem cells (PBSC) for bone marrow reconstitution, in order to limit tumor cell contamination and to shorten the cytopenic period. 6, 7 Recent reports have analyzed the use of positively selected CD34(+) stem cells. 8, 9 Ongoing trials using CD34(+) stem cells are currently under way.
We report the results of therapeutic intensification in 55 myeloma patients treated at the Centre Hospitalier Lyon Sud over a 6-year period. The majority of patients had chemosensitive disease, and 36% were 60 years old or more at the time of intensification. Fifteen patients underwent double intensification. A number of disease-or treatmentrelated factors were analyzed for their potential influence on overall and progression-free survival.
Patients and methods

Patient characteristics
Between January 1990 and September 1997, 55 patients received high-dose intravenous L-PAM, with or without total body irradiation (TBI) for multiple myeloma. Patient and treatment characteristics are shown in Table 1 . There were 31 males and 24 females. The median age at intensification was 58 years (range 25-66, and 20 patients were 60 years old or more). Nine patients had light chain myeloma. The median prior number of regimens received, excluding the high-dose cyclophosphamide for stem cell collection, was two (range 1-3). Thirty-one patients had received oral or intravenous L-PAM before intensification (median dose in the 55 patients: 75 mg/m 2 ). Five patients had received interferon before intensification. Twentyseven out of 47 patients (57%) for whom data were available had elevated serum ␤2 microglobulin at diagnosis. Forty-five patients were grafted in partial remission, 35 of whom were in first remission. Eight patients were grafted with stable disease and two with refractory disease. Delay between first treatment of myeloma and intensification. 
Intensification therapy
Criteria for response and progression
A complete remission was defined as the absence of paraprotein in serum and urine, less than 5% plasma cells, and the absence of dystrophic plasma cells on bone marrow aspirate. Decreases of paraprotein (quantified by immunofixation) of more than 90 and 50% were considered as very good and partial responses, respectively. Stable disease was defined as absence of change in paraprotein, and progressive disease as an increase of at least 25% in paraprotein. Progression was confirmed by analysis of paraprotein levels in all cases. The date of progression used to calculate freedom from progression (FFP) survival was the date of first observation of clinical or biological symptoms of relapse or progression: appearance of pain which could be related to progressive bone lesions by radiographic or tomodensitometric examinations, sustained increase of paraprotein of more than 25%, appearance of hypercalcemia due to progression, or appearance of cytopenia related to progressive plasmacytosis of bone marrow.
Statistical analysis
Survival curves were plotted according to the method of Kaplan and Meier and were compared by the log-rank test, using Statistica software. Overall survival was calculated after the first intensification (OS after intensification), and after the first treatment of myeloma (OS after first treatment). Freedom from progression was calculated after intensification. The following factors were analyzed in univariate analysis for their influence on survival: sex, age greater than 60 at time of intensification, type of immunoglobulin (light chain vs others), prior administration of more than 75 mg/m 2 of L-PAM (median dose of L-PAM received by the entire group) before intensification, prior administration of VAD chemotherapy, high serum ␤2 microglobulin at diagnosis, status of disease before and after transplantation, administration of TBI, and single vs double intensification. 1-109) . The median durations of neutropenia under 100/l and 500/l were 6 days and 8 days, respectively, after PBSC reinjection. These values were identical after the first and the second intensification. The median number of platelet transfusions required was two (range 0-20). The longest interval between stem cell reinfusion and last platelet transfusion was 87 days.
Results
PBSC collection and myeloid toxicity
Toxic deaths
One patient suffered failure of myeloid reconstitution and died 6 months after reinfusion with no signs of progressive disease. Three other patients died of treatment-related infection: one due to undocumented pneumopathy 7 weeks after reinfusion, one of cholecystitis 2 months after a second intensification and one of streptococcal septicemia 13 days after reinfusion of stem cells. The overall toxic death rate was 4/55 (7.2%).
Other toxicities
Five patients developed herpes zoster. Grade 3-4 mucositis required intravenous morphine in 75% of the patients for a median of 7 days. Prolonged anorexia and dysgueusia were observed in all patients who had received TBI.
Response and Survival
The median follow-up was 18 months after intensification and 30 months after first treatment of myeloma. After intensification, 27 patients achieved PR and 16 patients were in CR or VGPR. Three patients were not evaluable for response (two cases of early death and one lost to followup). The two patients with progressive disease responded. The overall response rate of the entire group was thus 43/55 (78%). The median FFP and OS after intensification were 22 months and greater than 48 months, respectively ( Figure 1 ). The projected median OS after first treatment of myeloma was 71 months (data not shown).
Overall survival after transplantation was significantly longer in patients grafted in first response rather than later during the course of the disease (3-year OS of 88% vs 62%, P = 0.04). However there was no significant difference between these two groups in OS since first treatment of myeloma (data not shown). There was a trend towards more prolonged OS after transplantation in patients younger than 60 years old (P = 0.09). The other factors examined in univariate analysis were not found to influence OS significantly, including serum ␤2 microglobulin levels at diagnosis. Freedom from progression was significantly longer in patients under 60 years of age (median of 24 vs 12 months, P = 0.04) (Figure 2 ), in patients who had received less than 75 mg/m 2 of L-PAM before intensification (median of 30 months vs 16 months, P = 0.014) (Figure 3 ) and in patients who had received TBI as part of their conditioning regimen (24 months vs 12 months, P = 0.02). 
Discussion
Myeloid reconstitution with PBSC rather than bone marrow in patients receiving high-dose therapy for multiple myeloma is justified for a number of reasons. First, PBSC grafts may be less contaminated by myeloma cells than bone marrow grafts. In the study by Attal, 5 the median proportion of plasma cells in the bone marrow graft was 9% (range 0-50%). Gazitt et al 10 have shown that after high-dose cyclophosphamide and GM-CSF myeloma cells tend to be mobilized later than CD34 + stem cells. 10 A second reason is the shorter period of aplasia, which may reduce the risk of toxic death, and make intensification feasible in elderly patients. Finally, thanks to reduced hospitalization time, PBSC are also cost effective as compared to high-dose L-PAM alone.
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In keeping with published series, our results suggest that high-dose therapy allows higher response rates and longer overall survival than conventional chemotherapy in patients with high risk myeloma. 6 However the treatment-related death rates in our series (7%) and those reported in the literature (3-27%) 6 ,12,13 remain significant. Furthermore, Bladé et al 14 have reported that potential candidates for intensification who received conventional chemotherapy had a median survival of 5 years. In a disease which currently remains incurable, unlike lymphoma or neuroblastoma, this raises the important question of optimal timing of high-dose therapy in patients with multiple myeloma and possible selection of patients who may benefit from this approach. Identification of risk factors for treatment-related death would be useful to exclude high risk patients, but would require the analysis of a very large series.
Currently, first-line intensification in chemosensitive patients is becoming the most widely used approach. Other possible strategies consist of front-line intensification, repeated intensification, intensification later in the course of the disease, and in induction of a graft-versus-myeloma effect after transplantation. 15 Bjorkstrand et al 16 have reported that some patients remain in prolonged PCR-negative CR after double intensification. In a study of 496 patients, Barlogie et al 12 have tested tandem repeats, with a median time interval between the two tranplants of 5 months. These authors reported a median overall survival of 41 months, which does not appear greater than that observed in most studies with a single intensification. It should be noted that most of our patients actually received at least two high-dose treatments: high-dose cyclophosphamide for stem cell collection, a regimen shown to be effective in multiple myeloma, and high-dose L-PAM. 17 Delayed intensification is theoretically an interesting option given the treatment-related mortality of high-dose therapy and the natural course of myeloma. Previous reports suggest that patients grafted early in the course of disease have longer OS. 18 Some of the main obstacles to delayed intensification are the poor tolerance of this procedure in elderly patients, the difficulty in performing stem cell collections in patients who have received prolonged alkylating agent therapy, and the higher treatment-related mortality observed in patients treated late in the course of disease. 19, 20 Our observation that FFP is shorter in patients who have received more than 75 mg/m 2 total dose of L-PAM before intensification is also in favor of a nonalkylating first-line regimen, such as VAD. Furthermore the prior administration of high total doses of L-PAM may be responsible for the induction of resistance mechanisms rendering the intensification less efficient. In our series one-third of patients were at least 60 years old. Stem cell collection and intensification were performed as in younger patients, as has been previously reported. 21 However, the freedom from progression was significantly shorter than in younger patients. We observed a trend (P = 0.09) towards a more prolonged OS in younger patients. This lack of significance may be due to the low number of deaths which have occurred in our population at the current follow-up. The difference in FFP between older and younger patients may be due to the fact that most of the elderly patients did not receive TBI or a second intensification. Alternatively, the type of disease observed in elderly patients may be more refractory to therapeutic intensification.
There is a need to determine prognostic factors to define which subgroups of patients with high risk myeloma benefit from high-dose therapy and which are particularly susceptible to developing complications. Although this procedure is feasible in elderly patients, the actual benefit of highdose therapy in this subgroup, which represents a large portion of all patients with myeloma, requires further evaluation.
